Committee on Drug Addiction

The Committee on Drug Addiction was one of the governmental bodies that dominated a comparatively underdeveloped pharmaceutical industry for much of the twentieth century. Composed of university researchers and regulatory gatekeepers, it concentrated on preventing new addictive compounds from coming to market, placing prevention at the center of the institutional response to drug risk.

Institutional Role

The book groups the Committee on Drug Addiction with the National Research Council, describing both as governmental agencies that shaped the pharmaceutical landscape when the industry was less developed. The account identifies the committee’s broad purpose rather than detailing its formal powers, membership, or particular decisions: its work was directed toward stopping potentially addictive compounds before they entered the market.

Prevention and the Limits of Treatment

The committee’s preventive orientation belongs to a history in which researchers sought to limit the supply of addictive drugs. By 1963, progressive researchers acknowledged that science could not design a perfect cure for addiction and that maintenance drugs could not resolve the problem overnight. The book sets this recognition against the enduring complexity of international trafficking and the psychosocial pain that can lead people to seek relief through drugs. Medication, in this account, could help but could not by itself repair complicated lives.

Historical Contrast

The Committee on Drug Addiction’s emphasis on preventing addictive compounds from reaching consumers contrasts with the later commercial environment described in the book. Purdue Pharma promoted OxyContin by presenting addiction risk as exceptionally low, while the medical movement to treat pain as the fifth vital sign and new pain-assessment standards encouraged more liberal treatment of pain. The comparison underscores a shift in emphasis—from institutional efforts to restrict the arrival of addictive drugs to a healthcare and marketing system increasingly oriented toward expanding opioid treatment.